How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

3,464 results for

Vitiligo

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

41. Antibiotics drive microbial imbalance and vitiligo development in mice. (Abstract)

Antibiotics drive microbial imbalance and vitiligo development in mice. Vitiligo is impacted by environmental triggers. We studied the contribution of the microbiome in FH mice, where depigmentation is mediated by tyrosinase-reactive T cells. Mice received oral antibiotics and were monitored for depigmentation. The microbiome was studied in fecal and skin samples by 16S rRNA analysis. Resulting T-cell distributions were evaluated. In untreated mice, pigment loss did not expand to the pelage (...) T cells and accumulation of skin Tregs. This treatment spurred a Bacteroides-dominated population of fecal bacteria. Reduced diversity is prominent especially after ampicillin treatment, when the gut is dominated by Pseudomonas species. In line with current concepts relating the microbiome and the immune system, we predict that dietary measures might promote skin health and delay vitiligo onset.Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.

2019 Journal of Investigative Dermatology

42. Noncultured Extracted Hair Follicle Outer Root Sheath Cell Suspension versus Noncultured Epidermal Cell Suspension in the Treatment of Stable Vitiligo. Full Text available with Trip Pro

Noncultured Extracted Hair Follicle Outer Root Sheath Cell Suspension versus Noncultured Epidermal Cell Suspension in the Treatment of Stable Vitiligo. Various treatment modalities exist for vitiligo, yet none of them are curative. Vitiligo is still considered a challenging disease to manage. Surgical treatment offers an excellent option for patients with stable vitiligo, especially those who fail to respond to medical treatment. Cell suspension techniques carry the advantage of covering large

2019 Journal of cutaneous and aesthetic surgery Controlled trial quality: uncertain

43. Home vs hospital narrowband UVB treatment by a hand-held unit for new-onset vitiligo: A pilot randomized controlled study. (Abstract)

Home vs hospital narrowband UVB treatment by a hand-held unit for new-onset vitiligo: A pilot randomized controlled study. To compare the efficacy and safety of narrowband ultraviolet B (NB-UVB) phototherapy in home vs in hospital for the management of limited new-onset vitiligo.Patients with new-onset vitiligo (<3 months) with <5% body surface area involvement were recruited and randomly assigned to either a home-based or a hospital-based treatment group. Both groups were administered NB-UVB (...) phototherapy thrice a week. The body surface area (BSA) involved with vitiligo, Vitiligo Area Scoring Index (VASI), the effectiveness of repigmentation, Vitiligo Quality of Life index (VitiQoL), and the cost of treatment were examined.A total of 100 patients completed the study. Patients in both groups exhibited improvements demonstrated by BSA and VSAI decrease. No significant differences were found between the two groups in terms of skin repigmentation (P > 0.05). Improvements in the VitiQoL scores were

2019 Photodermatology, photoimmunology & photomedicine Controlled trial quality: uncertain

44. Clinical and epidemiological characteristics of childhood vitiligo: a study of 701 patients from Brazil. (Abstract)

Clinical and epidemiological characteristics of childhood vitiligo: a study of 701 patients from Brazil. Vitiligo is an acquired pigmentary disorder that affects approximately 0.5-2% of the world's population, and 25% of cases begin before 10 years of age. Although prevalent, there are few studies on the characterization of childhood vitiligo.To evaluate the clinical and epidemiological characteristics of childhood vitiligo.Transverse study conducted by reviewing data records of patients under (...) the age of 18 in which disease onset occurred before 13 years of age.Predominance of females (62%). The most common subtype was generalized vitiligo (53.8%). The average age of disease onset was 5.9 years. The most affected initial site was head/neck (44.22%). The Koebner phenomenon was present in 38.2%, emotional triggering factors in 67.0% of the patients, halo nevus in 17.4%, and associated autoimmune disease in 6.5% of the patients. Family history of vitiligo was observed in 16.9% of the patients

2019 International Journal of Dermatology

45. Evaluation of the effect of combined intralesional injection of prostaglandin F2α with narrow band UVB phototherapy in treatment of resistant cases of vitiligo. (Abstract)

Evaluation of the effect of combined intralesional injection of prostaglandin F2α with narrow band UVB phototherapy in treatment of resistant cases of vitiligo. Background: Vitiligo is a chronic cutaneous disease characterized with hypopigmented patches that leave psychological impact on the patients. There is increasing need for new treatment modalities to shorten the duration of treatment of vitiligo with the least side effects. Objective: To explore the effect of intralesional injection (...) of prostaglandin F2α on the outcome of narrow band ultraviolet rays B (NBUVB) for patients with stable vitiligo. Patients and methods: The study included 27 stable vitiligo patients with overall symmetrical lesions. For each patient, one patch was treated with NBUVB alone (control side), while another symmetrical patch was treated with combined intralesional injection of prostaglandin F2α with NBUVB therapy, weekly for 3 months. Results: There was statistically significant improvement in the repigmentation

2019 Journal of Dermatological Treatment

46. Comorbid diseases of vitiligo: A 10-year cross-sectional retrospective study of an urban US population. (Abstract)

Comorbid diseases of vitiligo: A 10-year cross-sectional retrospective study of an urban US population. Vitiligo is associated with medical conditions, primarily autoimmune disorders; however, only a few studies in the United States have investigated these associations.Our purpose was to investigate the diseases associated with vitiligo in the New York, New York, population and evaluate if these associations differ by race/ethnicity and sex.In this retrospective study, we analyzed data (...) collected from the medical records of 1487 vitiligo patients seen at New York University during a 10-year period.Vitiligo patients had a statistically significant higher prevalence of hypothyroidism, multiple sclerosis, rheumatoid arthritis, idiopathic thrombocytopenic purpura, seronegative arthritis, pernicious anemia, myasthenia gravis, inflammatory bowel disease, lymphoma, and systemic lupus erythematosus. Rates of comorbid autoimmune diseases varied by race and sex.Medical charts did

2019 Journal of American Academy of Dermatology

47. Clinical and Spectrophotometric Evaluation of Skin Photoadaptation in Vitiligo Patients after a Short Cycle of NB-UVB Phototherapy. (Abstract)

Clinical and Spectrophotometric Evaluation of Skin Photoadaptation in Vitiligo Patients after a Short Cycle of NB-UVB Phototherapy. The phenomenon of photoadaptation to narrow-band ultraviolet B (NB-UVB) radiation has been previously described in vitiligo and has usually been clinically measured by the assessment of the minimal erythema dose (MED) after phototesting.To assess the photoadaptive response in vitiligo and healthy skin after NB-UVB phototherapy not only clinically, but also (...) by spectrophotometry.Fourteen patients affected by generalized vitiligo underwent NB-UVB phototherapy twice weekly for 12 weeks. Before and after phototherapy, a phototesting procedure was administered on vitiligo patches and adjacent healthy skin with a solar simulated radiation (SSR). Visual assessment of the MED took place after 24 h. A spectrophotometer was used to assess the a* value and the melanin index (MI*), as signs of skin erythema and pigmentation. The photoadaptation factor (MED-PF) and the a* photoadaptation

2019 Dermatology

48. A randomized pilot study to compare hair follicle cell suspensions prepared using trypsin alone versus trypsin in combination with collagenase type I for transplantation in vitiligo. (Abstract)

A randomized pilot study to compare hair follicle cell suspensions prepared using trypsin alone versus trypsin in combination with collagenase type I for transplantation in vitiligo. Noncultured extracted hair follicle outer root sheath cell suspension (NC-EHF-ORS-CS) is an upcoming surgical technique to treat stable vitiligo. Conventionally it employs trypsin to tap the hair follicle (HF) reservoir for autologous melanocytes and their precursors for transplantation. However, a perifollicular (...) with stable vitiligo. Three similar patches were randomized into three parallel treatment arms [(A) trypsin plus collagenase, (B) trypsin alone and (C) dermabrasion with vehicle alone]. Each patient's HF sample was divided and digested by the two methods, and transplanted as suspensions onto dermabraded patches, while a third dermabraded patch received the vehicle only. Suspensions were sent for laboratory analysis. Repigmentation was assessed over a follow-up of 6 months.There was a significant increase

2019 Clinical & Experimental Dermatology Controlled trial quality: uncertain

49. Clinical and Pathological Relevance of Drug-induced Vitiligo in Patients Treated for Metastatic Melanoma with Anti-PD1 or BRAF/MEK Inhibitors. Full Text available with Trip Pro

Clinical and Pathological Relevance of Drug-induced Vitiligo in Patients Treated for Metastatic Melanoma with Anti-PD1 or BRAF/MEK Inhibitors. Current therapies for metastatic melanoma (anti-PD1 and BRAF/MEK inhibitors) can cause drug-induced vitiligo. The aim of this study is to dermatologically define and histologically characterize this new type of vitiligo, and assess the clinical course of the disease. Fourteen patients with metastatic melanoma treated with immune or targeted therapy were (...) included in a dataset evaluating clinical data, vitiligo description and histopathological features. Vitiligo-like lesions occurred after a mean of 7.5 months from the start of the therapies (range 1-42 months), with a prevalence of the non-segmental variant (71.4%). Fifty percent of patients showed a clinical response (4 complete response and 3 partial response), 35.7% had stable disease, and one patient died after disease progression. Median survival from the start of the therapies was 32.5 months

2019 Acta Dermato-Venereologica

50. Open Label Pilot Study of 2% Tofacitinib for the Treatment of Refractory Vitiligo. Full Text available with Trip Pro

Open Label Pilot Study of 2% Tofacitinib for the Treatment of Refractory Vitiligo. Treatment options for vitiligo are limited and many cases remain refractory to first and second line treatments. Interferon-gamma signaling mediated by Janus kinase (JAK) has been implicated in the pathogenesis of vitiligo.1 Systemic administration of tofacitinib, a potent JAK1/3 inhibitor, has been effective in treating vitiligo in case reports,2 however, it is associated with infections, malignancies

2019 British Journal of Dermatology

51. Vitiligo Repigmentation with Melanoma Progression During Pembrolizumab Treatment. Full Text available with Trip Pro

Vitiligo Repigmentation with Melanoma Progression During Pembrolizumab Treatment. is missing (Short communication).

2019 Acta Dermato-Venereologica

52. The Evaluation of Vitiligous lesions Repigmentation after the Administration of Atorvastatin calcium salt and Simvastatin-acid sodium salt in patients with active vitiligo (EVRAAS), a pilot study: study protocol for a randomized controlled trial. Full Text available with Trip Pro

The Evaluation of Vitiligous lesions Repigmentation after the Administration of Atorvastatin calcium salt and Simvastatin-acid sodium salt in patients with active vitiligo (EVRAAS), a pilot study: study protocol for a randomized controlled trial. Vitiligo is a chronic skin disorder presenting with depigmentation, the pathogenesis of which is complex but the autoimmune theory is now preferred. Multiple immunologic processes, including stimulation of the T-helper (Th)1 response, formation (...) of autoreactive melanocyte-specific CD8+ T lymphocytes, a decrease in the blood concentration of T regulatory (Treg) cells, and an increase in interleukin (IL)-17 and interferon (IFN) concentration, have been shown to contribute to vitiligo progression and maintenance. The aim of this study is to evaluate the influence of simvastatin and atorvastatin on vitiligous lesions in patients with nonsegmental vitiligo (NSV). According to available data, statins act through several immunological pathways, potentially

2019 Trials

53. Efficacy of NB-UVB, microneedling with triamcinolone acetonide, and a combination of both modalities in the treatment of vitiligo: A comparative study. Full Text available with Trip Pro

Efficacy of NB-UVB, microneedling with triamcinolone acetonide, and a combination of both modalities in the treatment of vitiligo: A comparative study. 29291952 2019 01 03 2019 01 03 1097-6787 79 2 2018 Aug Journal of the American Academy of Dermatology J. Am. Acad. Dermatol. Efficacy of NB-UVB, microneedling with triamcinolone acetonide, and a combination of both modalities in the treatment of vitiligo: A comparative study. 365-367 S0190-9622(17)32894-3 10.1016/j.jaad.2017.12.054 Elshafy (...) 29 United States J Am Acad Dermatol 7907132 0190-9622 0 Anti-Inflammatory Agents F446C597KA Triamcinolone Acetonide IM Adolescent Adult Anti-Inflammatory Agents therapeutic use Combined Modality Therapy Female Humans Male Middle Aged Needles Patient Satisfaction Punctures Triamcinolone Acetonide therapeutic use Ultraviolet Therapy Vitiligo drug therapy radiotherapy therapy Young Adult 2017 08 21 2017 11 07 2017 12 13 2018 1 3 6 0 2019 1 4 6 0 2018 1 3 6 0 ppublish 29291952 S0190-9622(17)32894-3

2019 Journal of the American Academy of Dermatology Controlled trial quality: uncertain

54. Markedly Reduced Risk of Internal Malignancies in Patients With Vitiligo: A Nationwide Population-Based Cohort Study. (Abstract)

Markedly Reduced Risk of Internal Malignancies in Patients With Vitiligo: A Nationwide Population-Based Cohort Study. Recent studies indicated that the autoimmunity of vitiligo exerts effects on cells other than melanocytes, which confer reduced risks of both melanoma and nonmelanoma skin cancers in patients with vitiligo. However, the risk of internal malignancy in patients with vitiligo has not been elucidated.We conducted a population-based retrospective cohort study using data from (...) the Korean National Health Insurance claims database obtained from January 2007 to December 2016. All patients age 20 years or older with vitiligo who had at least two contacts with a physician from 2009 to 2016, during which a principal diagnosis was made, were identified (vitiligo group). Controls were randomly selected (two per patient with vitiligo) after frequency matching with the vitiligo group for age and sex during the same period (control group).A total of 101,078 patients with vitiligo

2019 Journal of Clinical Oncology

55. Six-year follow-up of vitiligo patients successfully treated with autologous non-cultured melanocyte-keratinocyte transplantation. (Abstract)

Six-year follow-up of vitiligo patients successfully treated with autologous non-cultured melanocyte-keratinocyte transplantation. Although autologous non-cultured melanocyte-keratinocyte transplantation is a treatment option for stable vitiligo, there is lack of long-term maintenance data for this specific treatment.To search for factors associated with long-term maintenance of patients with stable vitiligo successfully treated with melanocyte-keratinocyte transplantation.This was a single (...) -centre retrospective study including stable vitiligo patients who underwent successful melanocyte-keratinocyte transplantation in the National Center for Vitiligo, Riyadh, Saudi Arabia, between 1 January 2004 and 30 June 2015. Cox proportional hazard model was used to estimate factors associated with relapse at 6 years of followup. Co-variates included, gender, type of vitiligo, age at vitiligo onset, age at surgical procedure, disease duration, disease stability, affected body surface area, treated

2019 Journal of the European Academy of Dermatology and Venereology

56. Comparison of 311-nm Titanium:Sapphire laser and 308-nm excimer laser treatment for vitiligo: A randomized controlled non-inferiority trial. (Abstract)

Comparison of 311-nm Titanium:Sapphire laser and 308-nm excimer laser treatment for vitiligo: A randomized controlled non-inferiority trial. The 308-nm excimer laser (EL) has been widely used for localized vitiligo. The recently developed Titanium:Sapphire laser, emits a wavelength of 311 nm, would be expected to be as effective as excimer laser in treatment of vitiligo but few controlled trials have been reported. We sought to compare the efficacy and safety of the TSL and EL as vitiligo (...) treatments.A randomized controlled non-inferiority trial based on split-body was conducted. Patients with stable vitiligo between June 2016 and May 2017 were enrolled. Paired symmetrical vitiligo lesions were randomized to either the EL or TSL treatment group, and treated with a 308-nm EL or a 311-nm TSL twice weekly for 12 weeks. The extent of repigmentation was assessed every 4 weeks, and the non-inferiority margin was set to 10%. We also recorded any adverse events.Seventy-four paired lesions in 21

2019 Lasers in surgery and medicine Controlled trial quality: uncertain

57. Palmoplantar vitiligo: an overlooked entity. (Abstract)

Palmoplantar vitiligo: an overlooked entity. 30883893 2019 10 25 1468-3083 33 8 2019 08 Journal of the European Academy of Dermatology and Venereology : JEADV J Eur Acad Dermatol Venereol Palmoplantar vitiligo: an overlooked entity. e300-e303 10.1111/jdv.15578 Iacovelli P P San Gallicano Dermatological Institute, via Elio Chianesi 53, Rome, 00144, Italy. Filoni A A San Gallicano Dermatological Institute, via Elio Chianesi 53, Rome, 00144, Italy. Martorina F F San Gallicano Dermatological

2019 Journal of the European Academy of Dermatology and Venereology

58. Comparison of efficacy of cold trypsinization versus warm trypsinization in preparation of autologous noncultured epidermal cell suspension for treatment of stable vitiligo. (Abstract)

Comparison of efficacy of cold trypsinization versus warm trypsinization in preparation of autologous noncultured epidermal cell suspension for treatment of stable vitiligo. 30768811 2019 03 12 1468-3083 2019 Feb 15 Journal of the European Academy of Dermatology and Venereology : JEADV J Eur Acad Dermatol Venereol Comparison of efficacy of cold trypsinization versus warm trypsinization in preparation of autologous non-cultured epidermal cell suspension for treatment of stable vitiligo. 10.1111

2019 Journal of the European Academy of Dermatology and Venereology

59. Mechanisms of repigmentation induced by photobiomodulation therapy in vitiligo. Full Text available with Trip Pro

Mechanisms of repigmentation induced by photobiomodulation therapy in vitiligo. Photobiomodulation (PBM) therapy is based on the exposure of biological tissues to low-level laser light (coherent light) or light-emitting diodes (LEDs; noncoherent light), leading to the modulation of cellular functions, such as proliferation and migration, which result in tissue regeneration. PBM therapy has important clinical applications in regenerative medicine. Vitiligo is an acquired depigmentary disorder (...) resulting from disappearance of functional melanocytes in the involved skin. Vitiligo repigmentation depends on available melanocytes derived from (a) melanocyte stem cells located in the bulge area of hair follicles and (b) the epidermis at the lesional borders, which contains a pool of functional melanocytes. Since follicular melanoblasts (MBs) are derived from the melanocyte stem cells residing at the bulge area of hair follicle, the process of vitiligo repigmentation presents a research model

2019 Experimental Dermatology

60. Circulating CCL20: A potential biomarker for active vitiligo together with the number of Th1/17 cells. Full Text available with Trip Pro

Circulating CCL20: A potential biomarker for active vitiligo together with the number of Th1/17 cells. Vitiligo is an autoimmune disease with varying pathological features. Activation of the CCL20-CCR6 axis plays an important role in chronic inflammatory diseases. However, whether CCL20-CCR6 and Th1/17 cells are indicative of active vitiligo is unclear.To investigate the potential role of CCL20 and the involvement of Th1/17 and Tc1/17 cells in the mechanism in vitiligo.One hundred patients (...) with vitiligo, and 20 healthy controls were included. The serum and blister fluid IL-17, IFN-γ, CCL20, and CXCL10 were studied using enzyme-linked immunosorbent assays. The numbers of Th1/17 cells and Tc1/17 cells in circulation were quantified using flow cytometry. CCR6 mRNA in peripheral blood mononuclear cells (PBMCs) was analyzed by real-time polymerase chain reaction and the protein level was confirmed by western blotting. CCR6 and CCL20 expression in lesions was analyzed by immunohistochemistry.The

2019 Journal of dermatological science

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>